Sensitivity analysis of glucosamine for pain at short term
| Supplement | Variable | Number of studies (patients) | SMD (95% CI) | I², % | Meta-regression | |
| ES difference | p Value | |||||
| Glucosamine | ||||||
| Randomisation | ||||||
| Low risk | 6 (732) | −0.2 (−0.4 to 0.1) | 51 | |||
| Unclear | 4 (314) | −0.6 (−1.3 to 0.1) | 84 | −0.3 (−0.8 to 0.2) | 0.27 | |
| Allocation concealment | ||||||
| Low risk | 3 (525) | 0.0 (−0.1 to 0.2) | 6 | |||
| Unclear | 7 (521) | −0.5 (−0.8 to −0.1) | 70 | −0.4 (−0.9 to 0.0) | 0.06 | |
| Blinding | ||||||
| Low risk | 3 (556) | −0.0 (−0.2 to 0.2) | 24 | |||
| Unclear | 6 (437) | −0.4 (−0.9 to −0.0) | 76 | −0.3 (−0.8 to 0.2) | 0.20 | |
| High risk | 1 (53) | −0.8 (−1.3 to −0.2) | 0 | −0.7 (−1.6 to 0.1) | 0.10 | |
| Incomplete outcome | ||||||
| Low risk | 6 (839) | −0.1 (−0.3 to 0.1) | 55 | |||
| Unclear | 2 (78) | −1.0 (−1.5 to −0.6) | 0 | −1.0 (−1.5 to −0.4) | 0.001 | |
| High risk | 2 (129) | −0.3 (−0.6 to 0.1) | 0 | −0.2 (−0.7 to 0.3) | 0.35 | |
| Selective reporting | ||||||
| Low risk | 8 (968) | −0.1 (−0.3 to 0.1) | 48 | |||
| High risk | 2 (78) | −1.0 (−1.5 to −0.6) | 0 | −0.9 (−1.5 to −0.4) | 0.001 | |
| Other bias (funding) | ||||||
| Low risk | 5 (824) | 0.0 (−0.1 to 0.2) | 0 | |||
| Unclear | 4 (202) | −0.7 (−1.0 to −0.4) | 0 | −0.7 (−1.0 to −0.4) | <0.001 | |
| High risk | 1 (20) | −1.4 (−2.4 to −0.4) | 0 | −1.4 (−2.4 to −0.4) | 0.005 | |
| Study sample size | ||||||
| Large | 3 (628) | 0.1 (−0.1 to 0.2) | 0 | |||
| Small | 7 (418) | −0.5 (−0.8 to −0.2) | 57 | −0.5 (−0.9 to −0.2) | 0.003 | |
| OA site | ||||||
| Knee OA | 9 (824) | −0.3 (−0.6 to −0.1) | 70 | |||
| Hip OA | 1 (222) | 0.1 (−0.2 to 0.3) | 0 | 0.4 (−0.3 to 1.2) | 0.28 | |
ES, effect size.; I², measures of heterogeneity; OA, osteoarthritis; SMD, standardised mean difference.